Q J Med 2002; 95: 267-273
© 2002 Association of Physicians
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer
R.A. Sharma
From the Oncology Department, University of Leicester, Leicester Royal Infirmary, Leicester, UK
 |
Introduction
|
|---|
The formulation of aspirin from salicylate by Felix Hoffman
in 1897 represents an early example of translating a clinical
need to laboratory pharmacology, and consequently bringing a
new derivative of a drug to patients. Although Hippocrates recommended
a brew of willow leaves (rich in salicylates) for the relief
of the pain of childbirth around 400 BC, it was not until the
late nineteenth century that the use of salicylic acid became
widespread for the relief of pain and fever.
1 Since consumption
of salicylic acid caused significant gastric irritation, many
chemists sought to formulate more tolerable forms of this drug.
Felix Hoffman, working in the laboratory of Friedrich Bayer,
formulated a pure and stable form of acetyl salicylic acid,
which was given the name ‘a-spirin’.
2 Based on its
success, the first large-scale pharmaceutical company, Bayer
& Co., was established.
Over half a century later, as other non-steroidal anti-inflammatory drugs (NSAIDs) with . . . [Full Text of this Article]
|
Prostaglandin biosynthesis
|
|---|
|
Targetting COX-1 for cardiovascular protection
|
|---|
|
Sparing COX-1 while inhibiting COX-2
|
|---|
|
COX as a target for preventing cancer
|
|---|
|
Data from clinical trials
|
|---|
|
Conclusions
|
|---|
|
Acknowledgments
|
|---|
|
Notes
|
|---|
|
References
|
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
